Cybin outlined two proprietary clinical programs, HLP003 and HLP004, targeting major depressive disorder and generalized anxiety disorder, and reported positive Phase 2 safety and efficacy results. The company said HLP003 has received FDA Breakthrough Therapy Designation and is in Phase 3 studies for adjunctive treatment of major depressive disorder. Cybin expects topline data from the Phase 3 APPROACH study in Q4 2026. The presentation said Cybin has filed more than 350 patents, with more than 100 granted, and cited patent protection through at least 2041.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.